Disseminated Intravascular Coagulation (DIC) in Cancer

  • Hussain I. Saba
  • Genevieve A. Morelli
  • Rashid I. Saba
Part of the Cancer Treatment and Research book series (CTAR, volume 148)

Venous thromboembolism (VTE) and disseminated intravascular coagulation (DIC) are important complications of cancer. The relationship was recognized as early as 1800 when Professor Armand Trousseau noted that patients with idiopathic VTE frequently harbor an occult cancer [1, 2]. Prandoni reported a 7.6% incidence of cancer in 145 patients following idiopathic VTE [3]. In 2000, Schulman reported that 13% of patients in his study developed cancer after their initial diagnosis of primary VTE [4]. We reported that 26.2% of veteran patients were diagnosed to have cancer within 6 months after initial VTE as compared to 11.5% of the control group [5]. These studies emphasize that there is an intimate relation between VTE and cancer.


Tissue Factor Disseminate Intravascular Coagulation Acute Promyelocytic Leukemia Disseminate Intravascular Coagulation Activate Partial Thromboplastin Time 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Trousseau A. Phlegmasia alba dolens. In: Clinique medicale de l’Hotel-Dieu de Paris: JB Balleire et Fils, Paris, France, 1865:654–712.Google Scholar
  2. 2.
    Falanga A, Rickles FR. Management of thrombohemorrhagic syndromes (THS) in hematologic malignancies. Hematology Am Soc Hematol Educ Program 2007;2007:165–171.CrossRefGoogle Scholar
  3. 3.
    Prandoni P, Lensing AWA, Buller HR et al. Deep vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med 1992;327:1128–1133.PubMedCrossRefGoogle Scholar
  4. 4.
    Schulman S, Lindmarker P. Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. N Engl J Med 2000;342:1953–1958.PubMedCrossRefGoogle Scholar
  5. 5.
    Saba HI, Khalil FK, Morelli GA et al. Thromboembolism preceding cancer: A correlation Study. Am J Hematol 2003;72:109–114.PubMedCrossRefGoogle Scholar
  6. 6.
    Virchow RLK (1856). Thrombose und Embolie. Gefässentzündung und septische Infektion, Gesammelte Abhandlungen zur wissenschaftlichen Medicin. Frankfurt am Main: Von Meidinger & Sohn, 219–732.  Translation in Matzdorff AC, Bell WR (1998). Thrombosis and embolie (1846–1856). Canton, Massachusetts: Science History Publications.Google Scholar
  7. 7.
    Saba, HI, Morelli GA. The Pathogenesis and Management of Disseminated Intravascular Coagulation. Clin Adv Hematol Oncol 2006;4:919–926.PubMedGoogle Scholar
  8. 8.
    Rickles FR, Falanga A. Molecular basis for the relationship between thrombosis and cancer. Thrombo Res 2001;102:V215–224.CrossRefGoogle Scholar
  9. 9.
    Van de Water L, Tracy PB, Aronson D et al. Tumor cell generation of thrombin via functional prothrombinase assembly. Cancer Res 1985;45:5521–5525.Google Scholar
  10. 10.
    Hettasch JM, Bandarenko N, Burchette JL et al. Tissue transglutaminase expression in human breast cancer. Lab Invest 1996;75:637–645.PubMedGoogle Scholar
  11. 11.
    Nemerson Y. The tissue factor pathway of blood coagulation. In: Coleman RW, Hirsh J, Harder VJ, Salzman EW (eds). Hemostasis and thrombosis. Basic principles and clinical practice. Philadelphia (PA), USA: Lippincott, 1994, pp. 81–93.Google Scholar
  12. 12.
    Wada H, Sase T, Yamaguchi M. Hypercoagulant states in malignant lymphoma. Exp Oncol 2005;27:179–185.PubMedGoogle Scholar
  13. 13.
    Arbuthnot C, Wilde JT. Haemostatic problems in acute promyelocytic leukaemia. Blood Rev 2006;20:289–297.PubMedCrossRefGoogle Scholar
  14. 14.
    Koyama T, Nishida K, Ohdama S et al. Determination of plasma tissue factor antigen and its clinical significance. Br J Haematol 1994;87:343–347.PubMedCrossRefGoogle Scholar
  15. 15.
    Osterud B, Bjorklid E. The tissue factor pathway in disseminated intravascular coagulation. Semin Thromb Hemost 2001;27:605–617.PubMedCrossRefGoogle Scholar
  16. 16.
    Andoh K, Kubota T, Takada M et al. Tissue factor activity in leukemia cells. Special reference to disseminated intravascular coagulation. Cancer 1987;59:748–754.PubMedCrossRefGoogle Scholar
  17. 17.
    Zhang Y, Deng Y, Luther T et al. Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. J Clin Invest 1994;94:1320–1327.PubMedCrossRefGoogle Scholar
  18. 18.
    Ott I, Fischer EG et al. A role for tissue factor in cell adhesion and migration mediated by interaction with actin-binding protein. J Cell Biol 1998;140:1241–1253.PubMedCrossRefGoogle Scholar
  19. 19.
    Carmeliet P, Mackman N, Moons L et al. Role of tissue factor in embryonic blood vessel development. Nature 1996;383:73–75.PubMedCrossRefGoogle Scholar
  20. 20.
    Shoji M, Hancock WW, Abe K et al. Activation of coagulation and angiogenesis in cancer: immunohistochemical localization in situ of clotting proteins and vascular endothelial growth factor in human cancer. Am J Pathol 1998;152:399–411.PubMedGoogle Scholar
  21. 21.
    Contrino J, Hair G, Kreutzer DL et al. In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease. Nat Med 1996;2:209–215.PubMedCrossRefGoogle Scholar
  22. 22.
    Gordon SG, Benson B. Analysis of serum cancer procoagulant activity and its possible use as a tumor marker. Thromb Res 1989;56(3):431–440.PubMedCrossRefGoogle Scholar
  23. 23.
    Kozwich DL, Kramer LC, Mielicki WP et al. Application of cancer procoagulant as an early detection tumor marker. Cancer 1994;74:1367–1376.PubMedCrossRefGoogle Scholar
  24. 24.
    Gordon SG, Cross BA. An enzyme-linked immunosorbent assay for cancer procoagulant and its potential as a new tumor marker. Cancer Res 1990;50:6229–6234.PubMedGoogle Scholar
  25. 25.
    Gordon SG, Cross BA. A factor X-activating cysteine protease from malignant tissue. J Clin Invest 1981;67:1665–1671.PubMedCrossRefGoogle Scholar
  26. 26.
    Donati MB, Falanga A, Consonni R et al. Cancer procoagulant in acute nonlymphoid leukemia: relationship of enzyme detection to disease activity. Thromb Haemostasis 1990;64:11–16.Google Scholar
  27. 27.
    Rickles FR, Hair G, Schmeizl M et al. All-trans retinoic acid (ATRA) inhibits the expression of tissue factor in human progranulocytic leukemia cells. Thromb Haemostasis 1993;69:1042 (abstract).Google Scholar
  28. 28.
    Falanga A, Consonni R, Marchetti M et al. Cancer procoagulant in the human promyelocytic cell line NB4 and its modulation by all-trans-retinoic acid. Leukemia 1994;8: 156–159.PubMedGoogle Scholar
  29. 29.
    Koyama T, Hirosawa S, Kawamata N et al. All-trans retinoic acid upregulates thrombomodulin and downregulates tissue-factor expression in acute promyelocytic leukemia cells: distinct expression of thrombomodulin and tissue factor in human leukemic cells. Blood 1994;84:3001–3009.PubMedGoogle Scholar
  30. 30.
    Zhao W, Wang X, Guo W et al. Hemostatic abnormalities associated with acute promyelocytic leukemia and corrective effects of all-trans-retinoic acid or arsenic trioxide treatment. Chin Med J (Engl) 2000;113:236–240.Google Scholar
  31. 31.
    Falanga A, Iacoviello L, Evangelista V et al. Loss of blast cell procoagulant activity and improvement of hemostatic variables in patients with acute promyelocytic leukemia given all-trans-retinoic acid. Blood 1995;86:1072–1081.PubMedGoogle Scholar
  32. 32.
    Bell WR. The fibrinolytic system in neoplasia. Semin Thromb Hemost 1996;22:459–478.PubMedCrossRefGoogle Scholar
  33. 33.
    Parolini S, Flagiello D, Cinquetti A et al. Up-regulation of urokinase-type plasminogen activator in squamous cell carcinoma of human larynx. Br J Cancer 1996;74:168–1174.PubMedCrossRefGoogle Scholar
  34. 34.
    Dass K, Ahmad A, Azmi AS et al. Evolving role of uPA/uPAR system in human cancers. Cancer Treat Rev 2008;34:122–136.PubMedCrossRefGoogle Scholar
  35. 35.
    Hajjar KA. Cellular receptors in the regulation of plasmin generation. Thromb Haemostasis 1995;74:294–301.Google Scholar
  36. 36.
    Colucci M, Balconi G, Lorenzet R et al. Cultured human endothelial cells generate tissue factor in response to endotoxin. J Clin Invest 1983;71:1893–1896.PubMedCrossRefGoogle Scholar
  37. 37.
    Bevilacqua MP, Pober JS, Majeau GR et al. Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukin 1. Proc Natl Acad Sci USA 1986;83: 4533–4537.Google Scholar
  38. 38.
    Moore KL, Esmon CT, Esmon NL. Tumor necrosis factor leads to the internalization and degradation of thrombomodulin from the surface of bovine aortic endothelial cells in culture. Blood 1989;73:159–165.PubMedGoogle Scholar
  39. 39.
    Nachman RL, Hajjar KA, Silverstein RL et al. Interleukin 1 induces endothelial cell synthesis of plasminogen activator inhibitor. J Exp Med 1986;163:1595–1600.PubMedCrossRefGoogle Scholar
  40. 40.
    van Hinsberg VW, Bauer KA, Kooistra T et al. Progress of fibrinolysis during tumor necrosis factor infusions in humans. Concomitant increase in tissue-type plasminogen activator, plasminogen activator inhibitor type-1, and fibrin(ogen) degradation products. Blood 1990;76:2284–2289.Google Scholar
  41. 41.
    Cozzolino F, Torcia M, Miliani A et al. Potential role of interleukin-1 as the trigger for diffuse intravascular coagulation in acute nonlymphoblastic leukemia. Am J Med 1988;84:240–250.PubMedCrossRefGoogle Scholar
  42. 42.
    Altieri DC, Edgington TS. The saturable high affinity association of factor X to ADP-stimulated monocytes defines a novel function of the Mac-1 receptor. J Biol Chem 1988;263:7007–7015.PubMedGoogle Scholar
  43. 43.
    Conkling PR, Greenberg CS, Weinberg JB. Tumor necrosis factor induces tissue factor-like activity in human leukemia cell line U937 and peripheral blood monocytes. Blood 1988;72: 128–133.PubMedGoogle Scholar
  44. 44.
    Levy GA, Schwartz BS, Curtiss LK, Edgington TS. Plasma lipoprotein induction and suppression of the generation of cellular procoagulant activity in vitro. J Clin Invest 1981;67:1614–1622.Google Scholar
  45. 45.
    Hara Y, Steiner M, Baldini MG. Characterization of the platelet-aggregating activity of tumor cells. Cancer Res 1980;40:1217–1222.PubMedGoogle Scholar
  46. 46.
    Pearlstein E, Salk PL, Yogeeswaran G et al. Correlation between spontaneous metastatic potential, platelet-aggregating activity of cell surface extracts, and cell surface sialylation in 10 metastatic-variant derivatives of a rat renal sarcoma cell line. Proc Natl Acad Sci USA 1980;77:4336–4339.Google Scholar
  47. 47.
    Bevilacqua MP, Pober JS, Majeau GR et al. Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukin 1. Proc Natl Acad Sci USA 1986;83: 4533–4537.Google Scholar
  48. 48.
    Nawroth PP, Stern DM. Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med 1986;163:740–745.PubMedCrossRefGoogle Scholar
  49. 49.
    Falanga A. Tumor cell prothrombotic properties. Haemostasis 2001;31 Suppl 1:1–4.PubMedGoogle Scholar
  50. 50. dictionary entry. Accessed 7/23/08 (
  51. 51.
    Kerr JF; Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Brit J Cancer 1972;26:239–257.CrossRefGoogle Scholar
  52. 52.
    Wang J, Weiss I, Svoboda K et al. Thrombogenic role of cells undergoing apoptosis. Br J Haematol 2001;115:382–391.PubMedCrossRefGoogle Scholar
  53. 53.
  54. 54.
    Coiffier B, Altman A, Pui CH, Younes A, Cairo MS. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol 2008;26:2767–2778.PubMedCrossRefGoogle Scholar
  55. 55.
    Dvorak HF, Rickles FR. Malignancy and hemostasis. In: Colman RW, Marder VJ, Clowes AW, George JN, Goldhaber SZ, eds. Hemostasis and thrombosis, basic principles and clinical practice. Philadelphia, PA: Lippincott Williams & Wilkins; 2006:851–873.Google Scholar
  56. 56.
    Levi M. Cancer and DIC. Haemostasis 2001;31:47–48.PubMedGoogle Scholar
  57. 57.
    Blom JW, Doggen CJ, Osanto S, et al. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005;293:715–722.PubMedCrossRefGoogle Scholar
  58. 58.
    Sack GH Jr, Levin J, Bell WR. Trousseau's syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: clinical, pathophysiologic, and therapeutic features. Medicine (Baltimore) 1977;56:1–37.Google Scholar
  59. 59.
    Siegal T, Seligsohn U, Aghai E, et al. Clinical and laboratory aspects of disseminated intravascular coagulation (DIC): a study of 118 cases. Thromb Haemost 1978;39: 122–134.PubMedGoogle Scholar
  60. 60.
    Sallah S, Wan JY, Nguyen NP et al. Disseminated intravascular coagulation in solid tumors: clinical and pathologic study. Thromb Haemost 2001;86:828–833.PubMedGoogle Scholar
  61. 61.
    Colman RW, Rubin RN. Disseminated intravascular coagulation due to malignancy. Semin Oncol 1990;17:172–186.PubMedGoogle Scholar
  62. 62.
    Levi M. Disseminated intravascular coagulation: new diagnostic criteria and supportive treatment strategies. 47th Scientific and Standardization Committee Meeting of the International Society on Thrombosis and Haemostasis. July 6–7, 2001. Paris, France. Medscape Cardiology. 2001. Accessed 07/09/08.
  63. 63.
    Taylor FB Jr, Toh CH, Goots K et al. On behalf of the Scientific Subcommittee on Disseminated Intravascular Coagulation. Towards a definition, clinical and laboratory criteria and a scoring system for disseminated intravascular coagulation. Thromb Haemost 2001;86:1327–1330.PubMedGoogle Scholar
  64. 64.
    Toh CH, Downey C. Performance and prognostic importance of a new clinical and laboratory scoring system for identifying non-overt disseminated intravascular coagulation. Blood Coagul Fibrinolysis 2005;16:69–74.PubMedCrossRefGoogle Scholar
  65. 65.
    Toh CH, Hoots K. On behalf of the SSC on Disseminated Intravascular Coagulation of the ISTH. The scoring system of the Scientific and Standardisation Committee on disseminated intravascular coagulation of the International Society of Thrombosis and Haemostasis; A 5-year review. J Thromb Haemost 2007;5:604–606.Google Scholar
  66. 66.
    Gando S, Wada H, Asakura H, et al. Evaluation of new Japanese diagnostic criteria for disseminated intravascular coagulation in critically ill patients. Clin Appl Thrombosis/Hemostasis 2005;11(1):71–76.CrossRefGoogle Scholar
  67. 67.
    Horan JT, Francis CW. Fibrin degradation products, fibrin monomer and soluble fibrin in disseminated intravascular coagulation. Semin Thromb Hemost 2001;27: 657–666.CrossRefGoogle Scholar
  68. 68.
    Gupta PK, Gupta M, Chatterjee T et al. Comparative evaluation of whole blood d-dimer test to plasma d-dimer test for diagnosis of disseminated intravascular coagulation. Indian J Exp Biol 2005;43:382–384.PubMedGoogle Scholar
  69. 69.
    Yu M, Nardella A, Pechet L. Screening tests for disseminated intravascular coagulation: guidelines for rapid and specific laboratory diagnosis. Crit Care Med 2000;28:1777–1780.PubMedCrossRefGoogle Scholar
  70. 70.
    Marder VJ, Martin SE, Colman RW. Clinical aspects of consumptive thrombohemorrhagic disorders. In: Colman RW, Hirsh J, Marder WJ, Salzman EW. (eds). Hemostasis and thrombosis: basic principles and clinical practice 1998, p. 665.Google Scholar
  71. 71.
    Seligsohn U. Disseminated intravascular coagulation. In: Buetler E, Coller BS, Lichtman MA, Kipps TJ, Seligsohn U, (eds). Williams Hematology, 6th edn 2001, pp. 1677–1695.Google Scholar
  72. 72.
    Kruger D. Acute systemic disseminated intravascular coagulation: managing a complex medical condition. JAAPA 2006;19:28–32.PubMedGoogle Scholar
  73. 73.
    Bakhshi S, Arya LS. Diagnosis and treatment of disseminated intravascular coagulation. Indian Pediatr 2003;40:721–730.PubMedGoogle Scholar
  74. 74.
    Levi M, ten Cate H. Disseminated intravascular coagulation. New Engl J Med 1999;341: 586–592.PubMedCrossRefGoogle Scholar
  75. 75.
    Ten Cate H. Thrombocytopenia: one of the markers of disseminated intravascular coagulation. Pathophysiol Haemost Thromb 2003/2004;33:413–416.PubMedCrossRefGoogle Scholar
  76. 76.
    Wada H, Mori Y, Okabayashi K et al. High plasma fibrinogen level is associated with poor clinical outcome in DIC patients. Am J Hematol 2003;72:1–7.PubMedCrossRefGoogle Scholar
  77. 77.
    Wardle EN, Taylor G. Fibrin breakdown products and fibrinolysis in renal disease. J Clin Pathol 1968;21:140–146.PubMedCrossRefGoogle Scholar
  78. 78.
    Saito T, Takenaka M, Miyai I et al. Coagulation and fibrinolyolysis disorder in muscular dystrophy. Muscle Nerve 2001;24:399–402.PubMedCrossRefGoogle Scholar
  79. 79.
    Bick RL, Baker WF. Diagnostic efficacy of the d-dimer assay in disseminated intravascular coagulation. Thromb Res 1992;65:785–790.PubMedCrossRefGoogle Scholar
  80. 80.
    Mugler K, Lefkowitz JB. False-positive D-dimer result in a patient with Castleman disease. Arch Path Lab Med 2004;128:328–331.PubMedGoogle Scholar
  81. 81.
    Labelle CA, Kitchens CS. Disseminated intravascular coagulation: treat the cause, not the lab values. Cleve Clin J Med 2005;72:377–378.PubMedCrossRefGoogle Scholar
  82. 82.
    Mant MJ, King EG. Severe, acute disseminated intravascular coagulation. A reappraisal of its pathophysiology, clinical significance and therapy based on 47 patients. Am J Med 1979;67:557–563.Google Scholar
  83. 83.
    Schlaeppi MR, Korte W, von Moos R et al. Successful treatment of acute disseminated intravascular coagulation in a patient with metastatic melanoma. Onkologie 2006;29: 531–533.PubMedCrossRefGoogle Scholar
  84. 84.
    Huang TC, Yeh KH, Cheng AL et al. Weekly 24-hour infusional 5-fluorouracil as initial treatment for advanced gastric cancer with acute disseminated intravascular coagulation. Anticancer Res 2008;28(2B):1293–1297.PubMedGoogle Scholar
  85. 85.
    Tokar M, Bobilev D, Ariad S et al. Disseminated intravascular coagulation at presentation of advanced gastric cancer. IMAJ 2006;8:853–855.PubMedGoogle Scholar
  86. 86.
    Wakabayashi K, Hayashi S, Masuda H et al. A case of advanced gastric cancer with simultaneous multiple bone metastases and double occurrence of disseminated intravascular coagulation successfully controlled with combined chemotherapy. Gan To Kagaku Ryoho 2004;31:393–398.PubMedGoogle Scholar
  87. 87.
    Chakrapee-Sirisuk S, Amornpichetkul K, Visudhiphan S et al. Ketoconazole and Flutamide in the treatment of disseminated intravascular clotting from prostate cancer: a case report and review. J Med Assoc Thai 2001;84:1495–1501.PubMedGoogle Scholar
  88. 88.
    Chao Y, Teng HC, Hung HC et al. Successful initial treatment with weekly etoposide, epirubicin, cisplatin,5-fluorouracil and leucovorin chemotherapy in advanced gastric cancer patients with disseminated intravascular coagulation. Jpn J Clin Oncol 2000;30:122–125.PubMedCrossRefGoogle Scholar
  89. 89.
    Tallman MS, Abutalib SA, Altman JK. The double hazard of thrombophilia and bleeding in acute promyelocytic leukemia. Semin Thrombo Hemost 2007;33:330–338.CrossRefGoogle Scholar
  90. 90.
    Leavey RA, Kahn SB, Brodsky I. Disseminated intravascular coagulation – a complication of chemotherapy in acute myelomonocytic leukemia. Cancer 1970;26:142–145.PubMedCrossRefGoogle Scholar
  91. 91.
    Uchiumi H, Matsushima T, Yamane A et al. Prevalence and clinical characteristics of acute myeloid leukemia associated with disseminated intravascular coagulation. Int J Hematol 2007;86:137–142.PubMedCrossRefGoogle Scholar
  92. 92.
    Sarris AH, Kempin S, Berman E et al. High incidence of disseminated intravascular coagulation during remission induction of adult patients with acute lymphoblastic leukemia. Blood 1992;79:1305–1310.PubMedGoogle Scholar
  93. 93.
    Feinstein DI. Diagnosis and management of disseminated intravascular coagulation: the role of heparin therapy. Blood 1982;60(2):284–7.PubMedGoogle Scholar
  94. 94.
    Hoyle CF, Swirsky DM, Freedman L, Hayhoe FG. Beneficial effect of heparin in the management of patients with APL. Br J Haematol 1988;68:283–9.PubMedCrossRefGoogle Scholar
  95. 95.
    Oguma Y, Sakuragawa N, Maki M et al. Treatment of disseminated intravascular coagulation with low molecular weight heparin. Research Group of FR-860 on DIC in Japan. Semin Thromb Hemost 1990;16 Suppl:34–40.PubMedGoogle Scholar
  96. 96.
    Shirai K, Chaudhary UB. Use of low molecular weight heparin and aminocaproic acid in chronic DIC associate with prostate cancer – a case report. Sci World J 2007;7: 753–755.CrossRefGoogle Scholar
  97. 97.
    Prandoni P. Antithrombotic strategies in patients with cancer. Thromb Haemostasis 1997;78:141–144.Google Scholar
  98. 98.
    Laczkovics C, Grafenhofer H, Kaider A et al. Risk of recurrence after a first venous thromboembolic event in young women. Haematologica 2007;92:1201–1207.PubMedCrossRefGoogle Scholar
  99. 99.
    Rickles FR, Levine MN. Venous thromboembolism in malignancy and malignancy in venous thromboembolism. Haemostasis 1998;28:43–49.PubMedGoogle Scholar
  100. 100.
    Clagett GP, Anderson FA Jr, Geerts W et al. Prevention of venous thromboembolism. Chest 1998;114:531S–560S.PubMedCrossRefGoogle Scholar
  101. 101.
    Majumdar G. Idiopathic chronic DIC controlled with low molecular weight heparin: a case report. Blood Coag Fibrinol 1996;7:97–98.CrossRefGoogle Scholar
  102. 102.
    Garcia Fernandez JR, Lopez Berenguel F, Ais C. Long-term treatment with low molecular weight heparin, of chronic disseminated intravascular coagulation. Ann Med Interna 2003;20:191–194.Google Scholar
  103. 103.
    Rubin RN, Colman RW. Disseminated intravascular coagulation. Approach to treatment. Drugs 1992;44(6):963–71.PubMedCrossRefGoogle Scholar
  104. 104.
    Nand S, Messmore H. Hemostasis in malignancy. Am J Hematol 1990;35:45–55.PubMedCrossRefGoogle Scholar
  105. 105.
    Munter G, Hershko C. Increased warfarin sensitivity as an early manifestation of occult prostate cancer with chronic disseminated intravascular coagulation. Acta Haematol 2001;105(2):97–9.PubMedCrossRefGoogle Scholar
  106. 106.
    Green D. Management of bleeding complications of hematologic malignancies. Semin Thromb Hemost 2007;33:427–434.PubMedCrossRefGoogle Scholar
  107. 107.
    Zakarija A, Kwaan HC. Bleeding and thrombosis in the cancer patient. Expert Rev Cardiovasc Ther 2003;1:271–281.PubMedCrossRefGoogle Scholar
  108. 108.
    Arkel YS. Thrombosis and cancer. Semin Oncol 2000;27:362–374.PubMedGoogle Scholar
  109. 109.
    Kwaan HC. Double hazard of thrombophilia and bleeding in leukemia. Hematology Am Soc Hematol Educ Program 2007;2007:151–157.Google Scholar
  110. 110.
    Saito M, Asakura H, Jokaji H et al. Recombinant hirudin for the treatment of disseminated intravascular coagulation in patients with haematological malignancy. Blood Coagul Fibrinolysis 1995;6:60–64.PubMedCrossRefGoogle Scholar
  111. 111.
    Sallah S, Husain A, Nguyen NP. Recombinant activated factor VII in patients with cancer and hemorrhagic disseminated intravascular coagulation. Blood Coagul Fibrinolysis 2004;15:577–582.PubMedGoogle Scholar
  112. 112.
    Hatzipantellis E, Gombakis N, Sidi V et al. Successful outcome of DIC and life-threatening bleeding in a toddler with neuroblastoma treated with recombinant activated factor VII. Intern Emerg Med 2008;3:171–173.CrossRefGoogle Scholar
  113. 113.
    Prandoni P. How I treat venous thromboembolism in patients with cancer. Blood 2005;106:4027–33.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Hussain I. Saba
    • 1
  • Genevieve A. Morelli
    • 2
  • Rashid I. Saba
    • 3
  1. 1.Hemophilia-Hemostasis-Thrombosis Center, Department of Internal MedicineUniversity of South Florida College of MedicineTampaUSA
  2. 2.Department of Malignant HematologyH. Lee Moffitt Cancer Center and Research InstituteTampaUSA
  3. 3.Section of Hematology/ Oncology, Medical ServiceJames A. Haley Veterans Hospital, #111RTampaUSA

Personalised recommendations